Active Biotech: Positive Results in the First Stage of Naptumomab’s phase IIa Trial with Docetaxel
Redeye views the successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel as promising. We make an adjustment to our Base Case.
RR
Richard Ramanius
Disclosures and disclaimers